GSK PLC (GSK)
42.14
-0.05
(-0.12%)
USD |
NYSE |
Mar 18, 16:00
42.14
0.00 (0.00%)
Pre-Market: 07:06
GSK Enterprise Value: 99.86B for March 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 18, 2024 | 99.86B |
March 15, 2024 | 99.96B |
March 14, 2024 | 101.77B |
March 13, 2024 | 102.34B |
March 12, 2024 | 102.15B |
March 11, 2024 | 101.44B |
March 08, 2024 | 101.89B |
March 07, 2024 | 102.78B |
March 06, 2024 | 100.83B |
March 05, 2024 | 100.79B |
March 04, 2024 | 100.47B |
March 01, 2024 | 99.64B |
February 29, 2024 | 99.37B |
February 28, 2024 | 100.26B |
February 27, 2024 | 100.34B |
February 26, 2024 | 100.26B |
February 23, 2024 | 100.01B |
February 22, 2024 | 99.89B |
February 21, 2024 | 99.45B |
February 20, 2024 | 99.61B |
February 16, 2024 | 99.45B |
February 15, 2024 | 99.10B |
February 14, 2024 | 99.16B |
February 13, 2024 | 98.33B |
February 12, 2024 | 97.68B |
Date | Value |
---|---|
February 09, 2024 | 99.39B |
February 08, 2024 | 99.20B |
February 07, 2024 | 99.61B |
February 06, 2024 | 99.06B |
February 05, 2024 | 98.70B |
February 02, 2024 | 96.97B |
February 01, 2024 | 96.79B |
January 31, 2024 | 94.37B |
January 30, 2024 | 93.63B |
January 29, 2024 | 93.57B |
January 26, 2024 | 93.59B |
January 25, 2024 | 93.13B |
January 24, 2024 | 93.51B |
January 23, 2024 | 94.02B |
January 22, 2024 | 94.53B |
January 19, 2024 | 94.83B |
January 18, 2024 | 94.55B |
January 17, 2024 | 95.03B |
January 16, 2024 | 95.23B |
January 12, 2024 | 95.68B |
January 11, 2024 | 94.75B |
January 10, 2024 | 95.46B |
January 09, 2024 | 94.99B |
January 08, 2024 | 94.75B |
January 05, 2024 | 93.88B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.06B
Minimum
Sep 30 2022
151.95B
Maximum
Jan 18 2022
113.17B
Average
116.57B
Median
Enterprise Value Benchmarks
AstraZeneca PLC | 225.82B |
Haleon PLC | 48.25B |
Novo Nordisk A/S | 591.68B |
Sanofi SA | 127.98B |
Moderna Inc | 31.23B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 434.69M |
Revenue (Quarterly) | 10.00B |
Total Expenses (Quarterly) | 8.544B |
EPS Diluted (Quarterly) | 0.2111 |
Gross Profit Margin (Quarterly) | 69.97% |
Profit Margin (Quarterly) | 4.35% |
Earnings Yield | 6.63% |
Operating Earnings Yield | 9.95% |
Normalized Earnings Yield | 7.260 |